CRVO — CervoMed Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1053691 ·
Last close
$3.81
Market Cap
$35.28M
52W High
$7.45
52W Low
$2.13
ADV30
7,277,076
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -8,110,524 | -7,964,158 | 15,112,918 | 7,941,751 | 4,497,203 |
| Dec 2025 | 0 | — | -8,331,519 | -8,087,290 | 22,879,018 | 8,235,469 | 4,656,117 |
| Sep 2025 | 0 | — | -8,044,199 | -7,726,639 | 30,610,778 | 9,437,400 | 4,599,314 |
| Jun 2025 | 0 | — | -6,616,275 | -6,258,404 | 38,081,399 | 8,320,713 | 4,641,620 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-27,573,942
Investing CF
$20,411,492
Financing CF
$4,602,487
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.10
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-105,662,009
Inventory
—
Receivables
$0
ST Investments
$4,982,230
EBIT TTM
$-31,102,517
Pretax Income TTM
$-30,036,491
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,089,019
EBITDA
—
Free Cash Flow
$-16,304,171
Enterprise Value
$28,925,428
Total Cash
$12,923,981
Total Debt
$0
Shares Out
9,258,719
Trailing EPS
$-3.28
Book Value
$1.15
ROE
-132.8%
ROA
-72.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,294,877 | -26,966,367 | 22,879,018 | 4,656,117 | — | -23,449,963 |
| Dec 2024 | 0 | -18,227,131 | -16,290,695 | 43,081,610 | 3,879,282 | — | -16,530,827 |
| Dec 2023 | 0 | -7,812,895 | -2,171,873 | 9,972,521 | 2,595,747 | — | -7,449,847 |
| Dec 2022 | 0 | -3,475,534 | -5,803,047 | 4,157,706 | 37,442,765 | — | -2,572,759 |
TTM Snapshot
Revenues TTM
$12,839,780
NetIncome TTM
$-6,223,165
OpCashFlow TTM
$0
Assets (Latest)
$17,484,384
Forward EPS
$-2.42
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVC | ABVC BIOPHARMA, INC. | $35.36M | $1.36 | — |
| RADX | Radiopharm Theranostics Ltd | $34.80M | $4.41 | — |
| NSRX | Nasus Pharma Ltd | $36.07M | $3.08 | — |
| GRCE | Grace Therapeutics, Inc. | $34.35M | $2.22 | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $34.03M | $0.84 | — |
News headlines (Yahoo Finance, 1h cache)
CervoMed Insiders Lose Out As Stock Sinks To US$2.45
2026-06-14 12:14 · Yahoo
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-12 11:30 · Yahoo
Why Did CRVO Stock Crash 22% In Pre-Market Trading Today?
2026-06-10 12:34 · Yahoo
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
2026-06-10 11:30 · Yahoo
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-18 11:30 · Yahoo
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 23:05 · Yahoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-05 11:10 · Yahoo
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
2026-04-22 11:30 · Yahoo
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
2026-04-07 11:30 · Yahoo
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)
2026-03-25 19:28 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-06-15 17:37:36 | 2026-06-11 | Boger Joshua S | Dir, 10% | P - Purchase | 3.14 | 955414 | 3000000 |